Review top news and interview highlights from the week ending June 2, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The BLA has a PDUFA action date of November 25, 2023.
The assistant professor of microbiology at Penn Medicine discussed research into characterizing type 1 interferon and EGR2 signaling and their effects on CAR T-cell activation.
Genprex also announced preliminary data from the phase 1 portion of the trial evaluating Reqorsa, which is being presented at ASCO’s 2023 meeting.
The scientist at Senti Biosciences discussed developing small molecule-regulated gene circuits.
In more positive news, the company’s phase 2 trial for treating DMD will enroll patients in the second half of 2023.